# The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

> **NCT07114640** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Far Eastern Memorial Hospital** · enrollment: 220 (estimated)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Mirabegron 25mg
- **DRUG:** Solifenacin 5 mg
- **DRUG:** Tolterodine 4 mg
- **DRUG:** Oxybutynin ER 5 mg

## Key facts

- **NCT ID:** NCT07114640
- **Lead sponsor:** Far Eastern Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114640, "The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07114640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*